| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1345/APH.1P459 |
| P698 | PubMed publication ID | 21205950 |
| P2093 | author name string | Paul E Nolan | |
| Christopher R Ensor | |||
| William D Cahoon | |||
| Christopher A Paciullo | |||
| P2860 | cites work | The L-arginine-nitric oxide pathway | Q24304874 |
| Platelet activation and aggregation profile in prolonged external ventricular support | Q28209924 | ||
| Use of a continuous-flow device in patients awaiting heart transplantation | Q28244009 | ||
| Efficacy and safety of epoetin alfa in critically ill patients | Q28246281 | ||
| Inflammatory cytokine inhibition of erythropoiesis in patients implanted with a mechanical circulatory assist device. | Q51453198 | ||
| Left ventricular assist device-related infection: treatment and outcome. | Q51521286 | ||
| Use of recombinant factor VII to control bleeding in a patient supported by right ventricular assist device after heart transplantation. | Q51535199 | ||
| Infection in permanent circulatory support: experience from the REMATCH trial. | Q51564694 | ||
| Cardiac replacement with a total artificial heart as a bridge to transplantation. | Q51627532 | ||
| HeartMate VE LVAS design enhancements and its impact on device reliability. | Q51674488 | ||
| Bridge to transplantation with the Jarvik-7 (CardioWest) total artificial heart: a single-center 15-year experience. | Q51785803 | ||
| HeartMate II left ventricular assist system: from concept to first clinical use. | Q52066627 | ||
| Activation of endothelial and coagulation systems in left ventricular assist device recipients. | Q53370074 | ||
| Randomized, Double-Blind Trial of Inhaled Nitric Oxide in LVAD Recipients With Pulmonary Hypertension | Q57756353 | ||
| Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device | Q28252180 | ||
| Mechanical circulatory support: registering a therapy in evolution | Q28260624 | ||
| Clinical management of continuous-flow left ventricular assist devices in advanced heart failure | Q28274149 | ||
| Argatroban as a primary or secondary postoperative anticoagulant in patients implanted with ventricular assist devices | Q28277999 | ||
| Guidelines for the Early Management of Adults With Ischemic Stroke | Q28297859 | ||
| Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility | Q28574235 | ||
| Second INTERMACS annual report: more than 1,000 primary left ventricular assist device implants. | Q30425010 | ||
| Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro | Q33371349 | ||
| Cerebrovascular accidents in patients with a ventricular assist device. | Q33375726 | ||
| Acute left atrial thrombus after recombinant factor VIIa administration during left ventricular assist device implantation in a patient with heparin-induced thrombocytopenia | Q33378448 | ||
| Successful use and dosing of bivalirudin after temporary total artificial heart implantation: a case series | Q33381805 | ||
| Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support | Q33390013 | ||
| In vivo acute performance of the Cleveland Clinic self-regulating, continuous-flow total artificial heart | Q33635787 | ||
| The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. | Q33743667 | ||
| Abnormal von Willebrand factor in bleeding angiodysplasias of the digestive tract | Q33931597 | ||
| Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices | Q34015685 | ||
| Orthotopic cardiac prosthesis for two-staged cardiac replacement | Q34053015 | ||
| Infectious complications associated with ventricular assist systems | Q34100726 | ||
| Long-term use of a left ventricular assist device for end-stage heart failure. | Q34109624 | ||
| Thromboelastography: where is it and where is it heading? | Q34206893 | ||
| Critical care delivery in the intensive care unit: defining clinical roles and the best practice model | Q34392845 | ||
| Left ventricular assist device infections: three case reports and a review of the literature | Q34507829 | ||
| The interaction of varying doses of dipyridamole and acetyl salicylic acid on the inhibition of platelet functions and their effect on bleeding time | Q34518162 | ||
| ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiolo | Q34560910 | ||
| Allosensitization in heart transplantation: implications and management strategies | Q35090443 | ||
| Total artificial hearts: bridge to transplantation | Q35146917 | ||
| What Price Support? Ventricular Assist Device Induced Systemic Response | Q35549701 | ||
| Is severe right ventricular failure in left ventricular assist device recipients a risk factor for unsuccessful bridging to transplant and post-transplant mortality | Q35679144 | ||
| Lack of significant de novo HLA allosensitization in ventricular assist device recipients transfused with leukoreduced, ABO identical blood products | Q35924467 | ||
| Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant | Q35924900 | ||
| Development of mechanical heart devices | Q36141012 | ||
| The critical care clinical pharmacist: evolution of an essential team member | Q36396033 | ||
| Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices | Q36690439 | ||
| Recombinant activated factor VII in cardiac surgery: a systematic review | Q36720071 | ||
| Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery | Q48423059 | ||
| Technical report: analysis of citrated blood with thromboelastography: comparison with fresh blood samples. | Q48496503 | ||
| Advanced heart failure treated with continuous-flow left ventricular assist device | Q48952442 | ||
| Acquired von Willebrand syndrome in patients with ventricular assist device or total artificial heart | Q50199245 | ||
| Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis. | Q50670553 | ||
| Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. | Q50736515 | ||
| Suction events during left ventricular support and ventricular arrhythmias. | Q50937747 | ||
| Ventricular arrhythmias during left ventricular assist device support. | Q51024507 | ||
| The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. | Q51044872 | ||
| Initial experience with non-thoracic, extraperitoneal, off-pump insertion of the Jarvik 2000 Heart in patients with previous median sternotomy. | Q51210053 | ||
| Duration of inotropic support after left ventricular assist device implantation: risk factors and impact on outcome. | Q51282672 | ||
| Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. | Q51291989 | ||
| CardioWest total artificial heart: Bad Oeynhausen experience. | Q51392551 | ||
| Evidence-based treatment recommendations for uremic bleeding | Q36745397 | ||
| Transplant pharmacy: 30 years of improving patient care | Q36862304 | ||
| Acquired platelet dysfunction | Q36897703 | ||
| Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia | Q37100060 | ||
| Risk factors and outcomes of fungal ventricular-assist device infections | Q37158218 | ||
| Mechanical circulatory device thrombosis: a new paradigm linking hypercoagulation and hypofibrinolysis | Q37223336 | ||
| Role of cellular elements in thrombus formation and dissolution | Q37232984 | ||
| Current axial-flow devices--the HeartMate II and Jarvik 2000 left ventricular assist devices | Q37336445 | ||
| Incidence and patterns of adverse event onset during the first 60 days after ventricular assist device implantation | Q37390760 | ||
| Cardiac assist device infections | Q37527090 | ||
| The effectiveness of collaborative medicine reviews in delaying time to next hospitalization for patients with heart failure in the practice setting: results of a cohort study | Q37609698 | ||
| Increased incidence of gastrointestinal bleeding following implantation of the HeartMate II LVAD. | Q37717713 | ||
| PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. | Q37727128 | ||
| Preload sensitivity of the Jarvik 2000 and HeartMate II left ventricular assist devices | Q40089182 | ||
| Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease | Q40122861 | ||
| Does total implantability reduce infection with the use of a left ventricular assist device? The LionHeart experience in Europe | Q40235848 | ||
| Left ventricular assist device performance with long-term circulatory support: lessons from the REMATCH trial. | Q40465852 | ||
| Neurological events during long-term mechanical circulatory support for heart failure: the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) experience | Q40513058 | ||
| Inhaled nitric oxide: therapeutic applications in cardiothoracic surgery | Q40999557 | ||
| Ventricular arrhythmias after left ventricular assist device implantation | Q42569032 | ||
| LVAD bloodstream infections: therapeutic rationale for transplantation after LVAD infection | Q42605586 | ||
| Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy | Q43095005 | ||
| Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. | Q43173058 | ||
| Significance of anaemia in patients with advanced heart failure receiving long-term mechanical circulatory support | Q43269512 | ||
| Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. | Q43283940 | ||
| Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. | Q43849393 | ||
| Developing a comprehensive mechanical support program | Q43874697 | ||
| Rise of the machines--left ventricular assist devices as permanent therapy for advanced heart failure | Q44552924 | ||
| The total artificial heart: where we stand | Q44609675 | ||
| Management of wound and left ventricular assist device pocket infection | Q44775550 | ||
| Platelet dysfunction in outpatients with left ventricular assist devices | Q44855747 | ||
| Assessment of arterial blood pressure during support with an axial flow left ventricular assist device | Q44988823 | ||
| Isoproterenol in Pulmonary Hypertension | Q45141647 | ||
| Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device | Q45226411 | ||
| Heart transplantation in the United States, 1999-2008. | Q45399949 | ||
| Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). | Q45982333 | ||
| Haemolysis in patients with ventricular assist devices: major differences between systems. | Q45999076 | ||
| Low thromboembolic risk for patients with the Heartmate II left ventricular assist device | Q46233006 | ||
| Whole blood hypercoagulability despite anticoagulation during mechanical cardiac assist | Q46327310 | ||
| Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile HeartMate I and axial-flow HeartMate II devices | Q46415440 | ||
| A comparison of kaolin-activated versus nonkaolin-activated thromboelastography in native and citrated blood. | Q46441777 | ||
| Coagulation assays | Q46618544 | ||
| Worldwide experience with the MicroMed DeBakey Ventricular Assist Device as a bridge to transplantation | Q47630614 | ||
| A less invasive approach to axial flow pump insertion | Q47809043 | ||
| Fibrinolytic activation during long-term support with the HeartMate II left ventricular assist device | Q47970122 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacotherapy | Q701216 |
| P304 | page(s) | 60-77 | |
| P577 | publication date | 2011-01-04 | |
| P1433 | published in | Annals of Pharmacotherapy | Q4767858 |
| P1476 | title | Pharmacotherapy for mechanical circulatory support: a comprehensive review | |
| P478 | volume | 45 |
| Q59221048 | Antithrombotic therapy in ventricular assist device (VAD) management: From ancient beliefs to updated evidence. A narrative review |
| Q37046266 | Aspirin has limited ability to modulate shear-mediated platelet activation associated with elevated shear stress of ventricular assist devices. |
| Q35687180 | Chronic in vivo testing of the Penn State infant ventricular assist device |
| Q89506195 | Clinical pharmacology considerations for children supported with ventricular assist devices |
| Q34159316 | Comparative efficacy of in vitro and in vivo metabolized aspirin in the DeBakey ventricular assist device |
| Q36849839 | Multi-Targeted Antithrombotic Therapy for Total Artificial Heart Device Patients |
| Q36334445 | Multidrug-Resistant Organism Infections in Patients with Left Ventricular Assist Devices |
| Q88866756 | Pharmacotherapy considerations for long-term management of patients with left ventricular assist devices |
| Q24201292 | Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia |
| Q50081249 | Routine clinical anti-platelet agents have limited efficacy in modulating hypershear-mediated platelet activation associated with mechanical circulatory support. |
| Q34276182 | Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis |
| Q38261382 | Thrombosis in continuous-flow left ventricular assist devices: pathophysiology, prevention, and pharmacologic management |
Search more.